08 April 2014 : Case report
Rescue therapy with intravenous silibinin in liver transplant recipients with recurrent HCV hepatitis – two case reports
Łukasz SochaA, Ewa KarpińskaD, Krzysztof JurczykF, Łukasz LauransC, Dorota BanderB, Marta LachtaraBF, Marta Wawrzynowicz-SyczewskaAEDOI: 10.12659/AOT.889779
Ann Transplant 2014; 19:161-164
Abstract
Abstract
Background: Recurrence of hepatitis C virus (HCV) infection after liver transplantation is inevitable and decreases survival. Graft loss due to recurrent HCV occurs in 25% to 30% of patients. The recommended AASLD treatment is PEG-IFN, with or without ribavirin, but some patients might be not eligible for this treatment. An alternative antiviral agent is silibinin (SIL). In vitro silibinin stops replication, probably by inhibiting HCV RNA polymerase.
Case Report: We present the cases of 2 patients with severe recurrent HCV infection who received intravenous silibinin (IV SIL) as a “rescue therapy”. In the first patient with cholestatic fibrosing hepatitis, HCV RNA became undetectable. We also noted significant viremia reduction, and improvement in laboratory results and clinical presentation in the second patient.
Conclusions: Administration of IV SIL resulted in a rapid decrease of HCV viremia. In post-transplant patients with HCV recurrence who are not eligible for standard antiviral treatment, IV SIL can be considered as an alternative, but further investigations are necessary to establish treatment protocols.
Keywords: cholestatic fibrosing hepatitis, hepatitis C reinfection, silibinin, Liver Transplantation
Most Viewed Current Articles
24 Aug 2021 : Review article 22,652
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Sep 2015 : Review article 19,135
Risk Factors for Chronic Renal Insufficiency Following Cardiac TransplantationDOI :10.12659/AOT.893788
Ann Transplant 2015; 20:576-587
29 Dec 2021 : Original article 18,801
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
11 Aug 2015 : Original article 17,664
Twelve-Hour Hypothermic Machine Perfusion for Donor Heart Preservation Leads to Improved Ultrastructural Ch...DOI :10.12659/AOT.893784
Ann Transplant 2015; 20:461-468






